CLINICAL TRIALS PROFILE FOR JANUVIA
✉ Email this page to a colleague
All Clinical Trials for JANUVIA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00086502 ↗ | Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-06-01 | The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus. |
| NCT00086515 ↗ | Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-06-30 | The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus. |
| NCT00087516 ↗ | Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-06-01 | The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus. |
| NCT00289848 ↗ | MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-03-01 | This is a clinical study to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus. |
| NCT00337610 ↗ | Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-06-01 | A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy. |
| NCT00350779 ↗ | Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-06-12 | A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist combination therapy. |
| NCT00364377 ↗ | Incretins in Impaired Fasting Glucose | Completed | Mayo Clinic | Phase 4 | 2006-08-01 | People with high fasting glucose can develop type 2 diabetes with the passage of time. This study is being done to determine the effect of a novel medication in people with this elevated fasting glucose. Sitagliptin is a substance that raises levels of a hormone normally found in the blood. This hormone, called glucagon-like peptide-1 (GLP-1), is normally released by the intestine in response to the presence of food. This hormone acts like a messenger between the intestine and the pancreas to raise insulin levels, and therefore, lower blood sugars. Sitagliptin is effective in people with diabetes, however, this study is being done to determine if Sitagliptin is effective in people with high fasting glucose who do not yet have diabetes. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for JANUVIA
Condition Name
Clinical Trial Locations for JANUVIA
Trials by Country
Clinical Trial Progress for JANUVIA
Clinical Trial Phase
Clinical Trial Sponsors for JANUVIA
Sponsor Name
